The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
Adaptive Biotechnologies announced a worldwide collaboration and license agreement with Genentech – a member of the Roche Group – to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
GeoVax Labs and Enesi Pharma announced a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s novel MVA-VLP vaccine platform in combination with Enesi’s ImplaVax device and formulation technology.
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
bluebird bio Inc. and Gritstone Oncology Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.
Anima Biotech announced a deal with Eli Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform.
